Leiden, The Netherlands and Seattle (ots/PRNewswire) – ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has initiated a prospective, multi-center Phase II study with its lead product Fibrocaps at up to 20 sites, including major U.S. and Dutch academic medical centers. Jaap Koopman, CEO of ProFibrix said: [...]
Tag Archive > Prospective Multi Center
EANS-Adhoc: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Epigenomics AG Releases Preliminary PRESEPT Study Data
——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics 15.01.2010 Berlin, January 15, 2010 – Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular diagnostics company, informs on preliminary data [...]
EANS-News: Epigenomics AG: PRESEPT Study Subject Enrollment Successfully Completed
7,852 subjects prospectively enrolled including more than 50 cancer cases Blood samples selected for testing by independent biostatistics group Septin9 testing in three independent laboratories on track; majority of samples tested Completion of PRESEPT Study and reporting of top-line results expected for early 2010 ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely [...]
